Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q1 2026 (March 31)9holders −2
2new positions
4sold out
$1.40avg. 13F price*
At the end of Q1 2026, 9 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, down 2 from Q4 2025. 2 opened new positions and 4 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($12.6M), Ssi Investment Management LLC ($5.3M) and Loomis Sayles & Co. L P ($1.6M).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $5.5M |
| Exits | 4 | $11.8M |
All 13F filers, Q4 2025 → Q1 2026: 9,324,046 shares bought and 8,017,183 shares sold, net +1,306,863 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | Add +105.3% | 9,750,000 | $12.6M |
| Ssi Investment Management LLC | 0.43% | New | 4,098,000 | $5.3M |
| Loomis Sayles & Co. L P | 0.00% | Reduce -46.3% | 4,860 | $1.6M |
| Sei Investments Co. | 0.00% | No change | 251,000 | $322K |
| Bank of New York Mellon Corp | 0.00% | New | 215,000 | $277K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -1.2% | 81,000 | $104K |
| Boussard & Gavaudan Investment Management LLP | 0.01% | Add +52.7% | 32,000 | $41K |
| Stephens Inc. | 0.00% | No change | 24,000 | $31K |
| MML Investors Services, LLC | 0.00% | No change | 10,000 | $13K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.